Nano-targeted delivery of toremifene, an estrogen receptor-α blocker in prostate cancer

Pharmaceutical Research

Volumn 32, Issue 8, 2015, Pages 2764-2774

  Hariri, Waseem ^a   Sudha, Thangirala ^a   Bharali, Dhruba J ^a   Cui, Huadong ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Anti PSMA antibody; Estrogen receptor blocker; Nanomedicine. nano targeted therapy; Prostate cancer

Indexed keywords

MACROGOL; NANOCARRIER; POLYGLACTIN; TOREMIFENE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; PROSTATE SPECIFIC ANTIGEN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG SYNTHESIS; DRUG TUMOR LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULARLY TARGETED THERAPY; MOUSE; NANOENCAPSULATION; NANOMEDICINE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; NECROSIS; NUDE MOUSE; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ESTROGEN RECEPTOR ALPHA; HUMANS; MALE; MICE; MICE, NUDE; NECROSIS; PARTICLE SIZE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; TISSUE DISTRIBUTION; TOREMIFENE;

EID: 84961210420     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1662-x     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts & Figures 2014. 2014 September 10. Available from: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Khadige M, Peiffert D, Supiot S. What is the level of evidence of new techniques in prostate cancer radiotherapy? Cancer Radiother. 2014;18(5-6):501-8.
4. Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014;15(10):1147-56.
5. Stewart SB, Cheville JC, Sebo TJ, Frank I, Boorjian SA, Thompson RH, et al. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy. Prostate Cancer Prostatic Dis. 2014;17(4):332-7.
6. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, et al. Association of androgen deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2014. doi:10.1111/bju.12905.
7. Lee HY, Wu WJ, Huang CH, Chou YH, Huang CN, Lee YC, et al. Clinical predictor of survival following docetaxel-based chemotherapy. Oncol Lett. 2014;8(4):1788-92.
8. Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, et al. Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One. 2014;9(9):e104271.
9. Shigeta K, Kosaka T, Yazawa S, Yasumizu Y, Mizuno R, Nagata H, et al. Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer. Int J Clin Oncol. 2014. doi:10.1007/s10147-014-0746-7.
10. LaRocque J, Bharali DJ, Mousa SA. Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol. 2009;42(3):358-66.
11. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 2002;62(5):1370-6.
12. Mousa SA, Bharali DJ. Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications. Cancers. 2011;3(3):2888-903.
13. Holzmann C, Kilch T, Kappel S, Armbruster A, Jung V, Stockle M, et al. ICRAC controls the rapid androgen response in human primary prostate epithelial cells and is altered in prostate cancer. Oncotarget. 2013;4(11):2096-107.
14. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate. 2000;43(2): 150-7.
15. Ristau BT, O'Keefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2013;32(3):272-9.
16. Troyer JK, Beckett ML, Wright Jr GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62(5): 552-8.
17. Cao KY, Xu L, Zhang DM, Zhang XM, Zhang T, He X, et al. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. Int J Oncol. 2012;40(6):1977-85.
18. Su SL, Huang IP, Fair WR, Powell CT, Heston WD. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. 1995;55(7):1441-3.
19. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Adv Urol. 2012; 2012:Article ID 973820.
20. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6 Suppl 10:S13-8.
21. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009;55(3):533-42.
22. Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol. 2006;176(3): 965-70. discussion 970-961.
23. Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv. 2003;3(5):281-92.
24. Bharali DJ, Yalcin M, Davis PJ, Mousa SA. Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine. 2013;8(12): 1943-54.
25. Cho HS, Dong Z, Pauletti GM, Zhang J, Xu H, Gu H, et al. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano. 2010;4(9):5398-404.
26. Graf N, Bielenberg DR, Kolishetti N, Muus C, Banyard J, Farokhzad OC, et al. alpha(V)beta(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano. 2012;6(5):4530-9.
27. Bansal G, Maddhesia PK, Bansal Y. MS2/TOF and LC-MS/TOF studies on toremifene to characterize its forced degradation products. Analyst. 2011;136(24):5218-28.
28. Mazzarino M, Fiacco I, de la Torre X, Botre F. A mass spectrometric approach for the study of the metabolism of clomiphene, tamoxifen and toremifene by liquid chromatography time-of-flight spectroscopy. Eur J Mass Spectrom. 2008;14(3):171-80.
29. Sumantran VN. Cellular chemosensitivity assays: an overview. Methods Mol Biol. 2011;731:219-36.
30. Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol. 2005;16(1):63-72.
31. Kim IY, Kim BC, Seong DH, Lee DK, Seo JM, Hong YJ, et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. 2002;62(18):5365-9.
32. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res. 1990;50(19):6423-9.